Helixomer develops RNA origami-based therapeutics that utilize structural properties of RNA to create fast-acting, reversible anticoagulants. This technology addresses the need for safer blood thinners that minimize immunogenic responses while providing effective thrombin inhibition.
Funding
$350K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current anticoagulants carry risks of bleeding complications and may elicit immunogenic responses, creating a need for safer and more controllable blood-thinning agents. Existing therapies may also have slow onset or offset times, limiting their utility in acute settings.
Solution
Helixomer is developing RNA origami-based therapeutics designed as fast-acting, reversible anticoagulants. The technology leverages the structural properties of RNA to create molecules that inhibit thrombin, a key enzyme in the blood clotting cascade. These RNA origami structures offer the potential for rapid "on-off" action, providing precise control over anticoagulation. The platform aims to minimize immunogenic responses, enhancing safety and tolerability compared to traditional anticoagulants.
Target Audience
The primary target audience includes patients at risk of thromboembolic events, such as those undergoing surgery or with cardiovascular conditions, as well as clinicians seeking safer and more controllable anticoagulation options.
Features
- RNA origami-based aptamers designed for direct thrombin inhibition
- Fast "on-off" action for rapid initiation and reversal of anticoagulation
- Non-immunogenic design to minimize adverse immune reactions
- Tunable structure for optimized binding affinity and specificity